Blood cancer journal 2024 Apr 15
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Related Questions
The OS benefit with Zometa was seen only in patients with myeloma bone disease achieving less than or equal to a partial response. SRE risk reduction ...
New answer by Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center (April 24, 2024)
The excellent context within the question by @Craig C. Hofmeister answers 99% of what I was going to say. This is the MAGNOLIA trial that prompted this question:Lund et al., P...